Many individuals in the United States and all over the world have cancer, and the number of cancer patients is expected to even go higher in the coming years. Some doctors are however working towards reducing the number of his patients through their inventions, and Eric Lefkofsfky is one of the co-founders of Groupon to invent an effective medicine to improve the conditions of the people living with cancer. Though a many doctors use a more advanced technology in the diagnosis and treatment of the disease, many individuals including Eric frustrated on finding out that their relatives have the disease. Eric believes that a lot needs to be done to handle the data collected on the people living with cancer efficiently.
Besides, he has profoundly contributed to efficient way to handle such data through his Tempus platform, which seeks to provide the analytics software at an affordable rate. The company also focuses on the manner in which data on such victims is collected and handled, to give room for faster follow up especially in adverse conditions. On the other hand, the company also provides molecular data which they gather through human genome sequencing at a throwaway price.
Additionally, the company seeks to treat the disease in its cellular and molecular levels, and as a result, victims are identified early and guaranteed fast treatment. Eric believes that through the company’s technology, doctors will be more accurate and sure of whatever they are treating.
On the other hand, Eric has helped transform the field of medicine through his amendable technological skills and as a result saved the lives of many individuals. He has a lot of experience in his entrepreneurial field, and he started career by creating Starbelly company which is an internet forum.
He has partnered with various enterprises in the past years including Donovan Data Systems to improve his companies as well as business operations. Besides, the entrepreneur launched a charitable forum together with his wife, which aims at helping people, especially those with various problems including cancer. He has served to change the lives of many individuals, particularly the poor ones in the following: https://www.tempus.com/about-us/ click here.
Clay Siegall is one of the most well-known names in the world of biotechnology, pharmaceuticals, and cancer research. As a founder, CEO, and Chairman of one of the leading biotechnology firms in the United States known as Seattle Genetics, Clay Siegall has contributed immensely in the field of cancer therapies research. He has had a long and elaborate career in the field of pharmaceuticals and biotechnology and has gained popularity world over for his stream of achievements.
Seattle Genetics deals with research on different diseases types that have not seen any significant signs of mortality improvements in the last couple of decades. Clay Siegall is a highly qualified individual with Ph.D. in Genetics from the George Washington University and B.S. in Zoology from the Maryland University. Seattle Genetics started on a minuscule scale, but under the leadership of Clay Siegall, the company has made a marked place for itself in the research sector. The drug portfolio of the company continues to increase with time, and there are many new drugs under development presently as well.
Clay Siegall believes that the future of cancer therapies looks good as many new positive developments are taking place in the field that can potentially replace the currently administered cancer treatments. He believes that the old cancer treatment would be replaced with physicians relying more on targeted drugs that would be less painful, more tolerable, and highly efficient, at the same time.
In an interview recently, Clay Siegall mentioned that the idea to start Seattle Genetics came naturally to him as he was always interested in the field of medical science and the idea to intervene in the course of nature intrigued him. He became further determined with an idea to get involved and start his company when one of the family members was diagnosed with cancer and suffered terribly more due to the chemotherapy than due to cancer.
Under the leadership of Clay Siegall, Seattle Genetics has managed to raise funds well over $330 million and has partnered with many leading pharmaceutical companies, such as MedImmune, Bayer, CuraGen, and Progenics. Clay Siegall holds 15 patents to his name and has written many articles and book chapters for over 70 publications.